Kristie L. Kahl

Patients with multiple myeloma are living longer; therefore, their lifelong treatment expenses can become burdensome.

The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.

The phase 3 LUNAR trial evaluating tumor treating fields (TTFields) with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer (NSCLC).